Sensitivity analysis using bias functions for studies extending
  inferences from a randomized trial to a target population by Dahabreh, Issa J. et al.
This draft manuscript presents work in progress.
Comments and reports of mistakes are very much welcome at issa dahabreh@brown.edu.
Sensitivity analysis using bias functions for studies
extending inferences from a randomized trial to a target
population
Issa J. Dahabreh1,2,3,4, James M. Robins4,5, Sebastien J-P.A. Haneuse5, Iman Saeed1,2, Sarah E.
Robertson1,2, Elisabeth A. Stuart6, and Miguel A. Herna´n4,5
1Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI
2Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence,
RI
3Department of Epidemiology, School of Public Health, Brown University, Providence, RI
4Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston,
MA
5Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA
6Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, RI
6Departments of Mental Health, Biostatistics, and Health Policy and Management, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD
Tuesday 28th May, 2019
ar
X
iv
:1
90
5.
10
68
4v
1 
 [s
tat
.M
E]
  2
5 M
ay
 20
19
Abstract
Extending (generalizing or transporting) causal inferences from a randomized trial to a
target population requires “generalizability” or “transportability” assumptions, which
state that randomized and non-randomized individuals are exchangeable conditional
on baseline covariates. These assumptions are made on the basis of background knowl-
edge, which is often uncertain or controversial, and need to be subjected to sensitivity
analysis. We present simple methods for sensitivity analyses that do not require de-
tailed background knowledge about specific unknown or unmeasured determinants of
the outcome or modifiers of the treatment effect. Instead, our methods directly param-
eterize violations of the assumptions using bias functions. We show how the methods
can be applied to non-nested trial designs, where the trial data are combined with a
separately obtained sample of non-randomized individuals, as well as to nested trial
designs, where a clinical trial is embedded within a cohort sampled from the target
population. We illustrate the methods using data from a clinical trial comparing treat-
ments for chronic hepatitis C infection.
The distribution of effect modifiers among randomized individuals in clinical trials is often
different from that of individuals seen in clinical practice; consequently, average treatment
effects estimated in clinical trials do not directly apply to target populations beyond the
population represented by the randomized individuals [1]. Methods for extending (“general-
izing” or “transporting” [2]) causal inferences from a randomized trial to a target population
require exchangeability assumptions (“generalizability” or “exchangeability” assumptions),
which state that randomized and non-randomized groups are exchangeable conditional on
baseline covariates [3–6]. These assumptions are made on the basis of background knowledge,
which is often uncertain or controversial. Thus, investigators interested in extending infer-
ences beyond the population of randomized individuals need to conduct sensitivity analyses
to examine how potential violations of the assumptions would affect their findings.
The literature on sensitivity analysis for unmeasured confounding in observational studies
or for the related problem of data missing not-at-random is very extensive (starting with [7]
and expanded in various ways, e.g., [8–10]). In the context of analyses extending inferences
from a randomized trial to a target population, however, the only proposal for sensitivity
analysis methods that we are aware of is the work of Nguyen et al. [11, 12]. Their approach
can be useful when background knowledge is strong enough to suggest that a single variable
that would render randomized and non-randomized groups exchangeable has been measured
among the former but not among the latter. Their approach is less useful, however, in
the more typical case where violations of the exchangeability assumptions are due to high
dimensional unknown or unmeasured variables.
In this paper, we propose methods for sensitivity analysis that do not require detailed
background knowledge about or measurement of specific effect modifiers or determinants of
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the outcome. Instead, our methods parameterize violations of the exchangeability assump-
tion using bias functions expressed in terms of differences between the potential (counter-
factual) outcome means of randomized and non-randomized individuals.
To illustrate the methods, we take advantage of data from two centers participating in the
HALT-C trial comparing peginterferon alfa-2a treatment versus no treatment for patients
with chronic hepatitis C infection. We treat one of the centers as the “index center” and the
other as the “target center,” the latter providing a sample of individuals from a population
different from the index center (see [13] for a similar setup). Our goal is to transport causal
inferences from the index center to the population represented by the target center under a
mean exchangeability assumption, and to propose methods for sensitivity analysis when the
assumption does not hold. Because both centers were actually participating in the same trial,
and treatment and outcome data are available from both, we have the ability to compare the
estimates from our analyses against the randomization-based analyses in the target center.
The data structure in our application is the same as in any non-nested trial design, where
a clinical trial dataset is combined with a separately obtained sample from a population
of non-randomized individuals [14]. In the Appendix, we show how our methods can be
extended to nested trial designs, in which the randomized trial is nested within a cohort
sampled from the target population [5, 14].
1 Extending inferences to a target population
Consider a non-nested trial design, consisting of a randomized trial and a separately obtained
simple random sample of non-randomized individuals from the target population [6,14]. The
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data from this design consist of independent observations on baseline covariates, X; time-
fixed (non-time-varying) treatments, A; the outcome, Y ; and a trial participation indica-
tor, S (1 for randomized or 0 for non-randomized individuals). The data exhibit a special
missingness pattern: for randomized individuals we have data on (S = 1, X,A, Y ); for non-
randomized individuals we only have data on (S = 0, X) [5, 6].
Let Y a be the potential (counterfactual) outcome under intervention to set treatment
to a [15, 16]. We only consider binary treatments, such that a ∈ {0, 1}; extensions to
multivalued treatments are straightforward. In the main text of this paper, the causal
contrast of interest is the average treatment effect in the subset of non-randomized individuals
in the target population, E[Y 1 − Y 0|S = 0], which is identifiable both in non-nested and
nested trial designs. In general, this treatment effect is not equal to the treatment effect
among randomized individuals, E[Y 1−Y 0|S = 0] 6= E[Y 1−Y 0|S = 1]. In nested trial designs,
we can also identify the average treatment effect in the overall target population, E[Y 1−Y 0]
[5] (i.e., not just the non-randomized sub-population). In the main text of this paper, we
focus on identification, estimation, and sensitivity analysis methods for E[Y 1 − Y 0|S = 0]
because our motivating application only allows identification of that causal effect [6]; in
the Appendix we propose sensitivity analysis methods for studies that aim to draw causal
inferences about E[Y 1 − Y 0] [5].
1.1 Identifiability conditions
We now discuss sufficient conditions for identifying the potential outcome means among
non-randomized individuals, E[Y a|S = 0]. These means are of inherent scientific interest
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and can also be used to identify the causal contrast of interest, because E[Y 1− Y 0|S = 0] =
E[Y 1|S = 0]− E[Y 0|S = 0].
(I) Consistency: The observed outcome for the ith individual who received treatment a
equals that individual’s counterfactual outcome under the same treatment, that is, if Ai =
a, then Yi = Y
a
i . Implicit in this notation is the assumption that the invitation to participate
in the trial and trial participation do not affect the outcome except through treatment
assignment. In effect, we are making an exclusion restriction assumption of no direct effect
of trial participation on the outcome, such that potential outcomes need only be indexed by
treatment a, not trial participation s.
(II) Mean exchangeability in the trial (over A): Among randomized individuals, the poten-
tial outcome mean under treatment a is independent of treatment, conditional on baseline
covariates, E[Y a|X,S = 1, A = a] = E[Y a|X,S = 1].
(III) Positivity of treatment assignment: In the trial, the probability of being assigned to
each treatment, conditional on the covariates needed for exchangeability, is positive: Pr[A =
a|X = x, S = 1] > 0 for every a and every x with positive density among randomized
individuals, fX|S(x|S = 1) > 0.
(IV) Mean transportability (exchangeability over S): The potential outcome mean is indepen-
dent of trial participation, conditional on baseline covariates, E[Y a|X,S = 1] = E[Y a|X,S =
0] (provided the conditional expectations are well-defined). For binary S, this assumption is
equivalent to the mean generalizability assumption E[Y a|X,S = 1] = E[Y a|X].
(V) Positivity of trial participation: The probability of participating in the trial, conditional
on the covariates needed to ensure conditional mean transportability, is positive, Pr[S =
1|X = x] > 0 for every x with positive density in the population, fX(x) > 0.
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Note that we have used X generically to denote baseline covariates. It is possible, how-
ever, that strict subsets of X are adequate to satisfy each exchangeability condition. For
example, in a marginally randomized trial, the mean exchangeability among trial participants
holds unconditionally.
Consistency, mean exchangeability, and positivity of treatment assignment are expected
to hold in (marginally or conditionally) randomized clinical trials of well-defined interven-
tions. In order to focus our attention on issues related to selective trial participation, we
assume complete adherence to treatment assignment and no loss to follow-up in the trial.
Mean transportability and positivity of trial participation are the assumptions that allow
us to extend causal inferences beyond the randomized trial. Positivity of trial participation
is, in principle, testable [17]. In contrast, the mean transportability condition is not testable
using the observed data; in many applications, it is a controversial or uncertain assumption.
1.2 Identification of potential outcome means
The conditions listed above are sufficient to identify the conditional potential outcome mean
in the population of non-randomized individuals using only the observed data [6],
E[Y a|S = 0] = E[E[Y |X,S = 1, A = a]∣∣S = 0]. (1)
In other words, provided that identifiability conditions I through V hold, the observed data
functional, E
[
E[Y |X,S = 1, A = a]∣∣S = 0], can be interpreted as the potential outcome
mean had non-randomized individuals received treatment a. This functional can be re-
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expressed using inverse odds (IO) of participation weighting [6],
E
[
E[Y |X,S = 1, A = a]∣∣S = 0] = 1
Pr[S = 0]
E
[
SI(A = a)Y Pr[S = 0|X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
, (2)
where I(A = a) is the indicator function that takes value 1 when A = a and zero otherwise.
Furthermore, under the positivity conditions,
Pr[S = 0] = E
[
SI(A = a) Pr[S = 0|X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
, (3)
which will be useful in deriving estimators for the functional. Note that in non-nested designs,
expectations and probabilities are with respect to the distribution induced by the study
design [18, 19] (i.e., the separate sampling of randomized and non-randomized individuals,
with unknown sampling probability for non-randomized individuals [6, 14]).
1.3 Estimation and inference
1.3.1 Estimation
We briefly review [6] estimators of potential outcome means and treatment effects in the
population of non-randomized individuals. All estimators use data on Oi, i = 1, . . . , n,
where n is the total number of randomized and non-randomized individuals contributing
data to the analysis, and
O =

(X,S = 1, A, Y ), for randomized individuals;
(X,S = 0), for non-randomized individuals.
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Potential outcome means: We can estimate potential outcome means using estimators
that rely on modeling the outcome mean, the probability of trial participation, or both.
Outcome model-based (g-formula) estimator: We can use the sample analog estimator based
on (1):
µ̂OR(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)ĝa(Xi), (4)
where ĝa(X) is an estimator for E[Y |X,S = 1, A = a]. In applied analyses, it is impossible to
nonparametrically estimate this conditional mean because of the curse of dimensionality [20],
and we need to make modeling assumptions. Typically, we posit a parametric model ga(X; θ),
with finite dimensional parameter θ. When using such a model, the validity of the g-formula
estimator depends on correct model specification, in addition to the identifiability conditions.
IO weighting: Using (2), we can obtain an IO weighting estimator,
µ̂IOW1(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)Yi, (5)
where
ŵa(Xi, Si, Ai) = SiI(Ai = a)
1− p̂(Xi)
p̂(Xi)êa(Xi)
,
p̂(X) is an estimator for Pr[S = 1|X], and êa(X) is an estimator for Pr[A = a|X,S = 1].
Alternatively, combining (2) and (3), we can normalize the weights to sum to 1,
µ̂IOW2(a) =
{
n∑
i=1
ŵa(Xi, Si, Ai)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)Yi. (6)
As for the outcome model-based estimator, in applications, it is impossible to nonpara-
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metrically estimate the conditional probability of trial participation Pr[S = 1|X] and we
have to make modeling assumptions. Typically, we posit a parametric model p(X; β) for
Pr[S = 1|X], with finite-dimensional parameter β. When using such a model, the validity of
the IO weighting estimators depends on correct model specification, in addition to the identi-
fiability conditions. The conditional probability of treatment among randomized individuals
Pr[A = a|X,S = 1] is known and does not have to be estimated; in the presence of baseline
covariate imbalances between the randomized groups, however, it is useful to estimate it
using a parametric model, say, ea(X; γ), with finite-dimensional parameter γ [21–25].
Augmented IO weighting: To improve the efficiency of the IO weighting estimator and gain
robustness to misspecification of the models for the conditional outcome mean or the proba-
bility of trial participation, we can use the augmented (doubly robust) IO weighting estimator
µ̂AIOW1(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
{
ŵa(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+ (1− Si)ĝa(Xi)
}
. (7)
Again, we can normalize the weights to sum to 1,
µ̂AIOW2(a) =
{
n∑
i=1
ŵa(Xi, Si, Ai)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)ĝa(Xi).
(8)
These two estimators are “doubly robust” in the sense that they produce valid results
when either the model for the probability of trial participation or the model for the condi-
tional outcome mean among randomized individuals is correctly specified.
Treatment effects: We can use the potential outcome mean estimators to estimate
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the average treatment effect in the target population of non-randomized individuals, E[Y 1−
Y 0|S = 0], by differencing. For instance, we can estimate the average treatment effect using
the augmented IO weighting estimator with normalized weights as µ̂AIOW2(1)− µ̂AIOW2(0).
1.3.2 Inference
Confidence intervals for the estimated potential outcome means and mean differences can
be obtained by the usual “sandwich” approach [26] or by bootstrap methods [27]. Both
approaches can account for uncertainty in estimating the parameters of the model for the
probability of trial participation or the model for the outcome mean.
2 Sensitivity analysis for violations of the transporta-
bility assumption
2.1 Violations of the transportability assumption
The validity of all the estimators in the previous section depends critically on the mean
transportability assumption. In most applications, however, it is unlikely that we know or
can measure enough baseline variables to ensure that the assumption holds. Thus, we need
to consider the impact of assumption violations, when
E[Y a|X,S = 1] 6= E[Y a|X,S = 0].
The magnitude of the violations, that is, the magnitude of the difference between the condi-
tional potential outcome means E[Y a|X,S = 1] and E[Y a|X,S = 0], determines the amount
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of bias. Because this magnitude cannot be assessed using the data, we need to conduct sen-
sitivity analyses to examine the impact of violations of the condition affect on our results [9].
2.2 Sensitivity analysis with bias functions
2.2.1 Bias functions
Following prior work on sensitivity analysis for marginal structural causal models [9,28,29],
we parameterize violations of the mean transportability condition using a “bias function”
for each treatment a, defined as
u(a,X) ≡ E[Y a|X,S = 1]− E[Y a|X,S = 0]. (9)
Intuitively, u(a,X) expresses violations of the transportability assumption for each treatment
a as a function of the potential outcome means between randomized and non-randomized
individuals, conditional on (within strata of) the measured covariates X.
Parameterizing the violations of the transportability assumption allows us to re-express
the conditional potential outcome mean under treatment a among non-randomized individ-
uals. First, by re-arranging the definition in (9), we obtain E[Y a|X,S = 0] = E[Y a|X,S =
1] − u(a,X). Next, under consistency (condition I), exchangeability of the treated and un-
treated groups in the trial (condition II), and positivity of treatment assignment in the trial
(condition III), we have that E[Y a|X,S = 1] = E[Y |X,S = 1, A = a]. Putting everything
together,
E[Y a|X,S = 0] = E[Y |X,S = 1, A = a]− u(a,X). (10)
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Using the law of iterated expectation and (10),
E[Y a|S = 0] = E[E[Y a|X,S = 0]∣∣S = 0]
= E
[
E[Y |X,S = 1, A = a]− u(a,X)∣∣S = 0]
= E
[
E[Y |X,S = 1, A = a]∣∣S = 0]− E[u(a,X)|S = 0],
(11)
where the first term in the last expression is identifiable from the data, regardless of whether
the transportability condition holds, and the second term is also identifiable for each user-
specified u(a,X) function.
2.2.2 Sensitivity analysis
The result in (11) suggests simple approaches for sensitivity analysis using the potential
outcome mean estimators in the previous section.
Outcome model-based (g-formula) estimator: We can modify the outcome model-based esti-
mator to directly incorporate the bias correction,
µ̂bc
OR
(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)
{
ĝa(Xi)− u(a,Xi)
}
. (12)
IO weighting: Similarly, we can modify the IO weighting estimators as
µ̂bc
IOW1
(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
{
ŵa(Xi, Si, Ai)Yi − (1− Si)u(a,Xi)
}
, (13)
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or, normalizing the weights to sum to 1,
µ̂bc
IOW2
(a) =
{
n∑
i=1
ŵa(Xi, Si, Ai)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)Yi
−
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)u(a,Xi).
(14)
In the Appendix, we show how the bias correction for the IO weighting estimators can be
easily implemented using standard regression software, by simply re-coding the outcome
values to directly incorporate the bias correction function u(a,X).
The validity of the estimators in equations (12) through (14) depends on the correct
choice of the bias functions u(a,X) and, when relying on parametric models, the correct
specification of the models for the mean outcome among randomized individuals, ga(X; θ),
or the probability of trial participation conditional on covariates, p(X; β). By correct spec-
ification we mean that the models ga(X; θ) and p(X; β) should be good approximations of
the corresponding conditional mean/probability functions. Correct model specification is
distinct from the mean transportability condition: informally, correct model specification
addresses differences between randomized and non-randomized individuals with respect to
measured variables ; the bias functions address residual differences due to unmeasured or
unknown variables.
Augmented IO weighting: We can incorporate the bias correction functions in the augmented
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IO weighting estimators,
µ̂bc
AIOW1
(a) =
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
{
ŵa(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+ (1− Si)
{
ĝa(Xi)− u(a,X)
}}
,
(15)
or, normalizing the weights to sum to 1,
µ̂bc
AIOW2
(a) =
{
n∑
i=1
ŵa(Xi, Si, Ai)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+
{
n∑
i=1
(1− Si)
}−1 n∑
i=1
(1− Si)
{
ĝa(Xi)− u(a,Xi)
}
.
(16)
These estimators retain the double robustness property of their non-bias corrected coun-
terparts, in the sense that, when the bias correction function is correctly specified, they
produce valid results when either the model of the outcome mean among randomized indi-
viduals or the model for the probability of trial participation is correctly specified.
Sensitivity analysis for treatment effects: As when the transportability condition
holds, we can perform sensitivity analysis for treatment effects by differencing the appropriate
bias-corrected estimators.
Inference for sensitivity analysis: The general theory in [9] shows that valid con-
fidence intervals for the estimated bias-corrected potential outcome means and mean dif-
ferences can also be obtained by “sandwich” or bootstrap [27] methods, while accounting
for the uncertainty in estimating the parameters of the model for the probability of trial
participation.
In the Appendix we discuss the identification, estimation, and sensitivity analysis for
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potential outcome means and average treatment effects in the overall target population (i.e.,
not just the non-randomized subset of the population).
2.3 Choosing bias functions in practice
We cannot identify the bias functions u(a,X) using the data. Instead, we can use different
bias functions to conduct sensitivity analyses. To develop some intuition about the choice
of functions, note that u(a,X) quantifies the degree of selection into the trial on the basis
of potential outcome Y a. For instance, suppose that greater outcome values are preferred
(e.g., the outcome is a quality of life score with higher values indicating higher quality).
If we believe that, conditional on measured covariates, randomized individuals have better
outcomes than non-randomized individuals in the absence of treatment, that is, we believe
that E[Y 0|X,S = 1] > E[Y 0|X,S = 0], then we should select u(0, X) > 0. Conversely, if we
believe that randomized individuals have worse outcomes than non-randomized individuals
in the absence of treatment, that is, we believe that E[Y 0|X,S = 1] < E[Y 0|X,S = 0], then
we should select u(0, X) < 0.
Now, define the difference of the bias functions, δ(X),
δ(X) ≡ u(1, X)− u(0, X)
=
{
E[Y 1|X,S = 1]− E[Y 1|X,S = 0]
}
−
{
E[Y 0|X,S = 1]− E[Y 0|X,S = 0]
}
=
{
E[Y 1|X,S = 1]− E[Y 0|X,S = 1]
}
−
{
E[Y 1|X,S = 0]− E[Y 0|X,S = 0]
}
= E[Y 1 − Y 0|X,S = 1]− E[Y 1 − Y 0|X,S = 0].
This calculation shows that the difference of the bias functions equals the difference of the
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conditional average treatment effects given X among trial participants and non-participants.
In other words, the difference of the bias functions reflects the “residual,” unexplained by
X, effect modification over the participation indicator.
For instance, suppose, as above, that greater outcome values are preferred and that
we believe that δ(X) > 0, that is, u(1, X) > u(0, X). This corresponds to a belief that
individuals who choose to participate in the trial benefit more (or are harmed less) from
a = 1 than a = 0, compared to individuals who choose not to participate. A similar
argument shows that, when higher values of the outcome are preferred, δ(X) < 0 means
that individuals who choose to participate in the trial benefit less (or be harmed more) from
a = 1 than a = 0, compared to individuals who choose not to participate. In the special
case of δ(X) = 0, the conditional average treatment effect among randomized and non-
randomized individuals is the same, meaning that trial participants are not selected based
on the magnitude of the benefit (or harm) they might experience from treatment.
This interpretation of u(0, X) and δ(X) suggests a convenient way to perform sensitivity
analysis. For simplicity, we might use functions that do not depend on covariates, such
that u(0, X) ≡ u(0) and δ(X) ≡ δ. Clearly, each choice of a pair of values for (u(0), δ)
implies a choice of u(1) = δ + u(0). The sensitivity analysis, then, examines the impact of
a sufficiently diverse set of
(
u(0), δ
)
pairs on inferences about potential outcome means and
average treatment effects, using the estimators in Section 2.2.2.
Arguably, allowing the bias functions to vary over baseline covariates is more realistic.
When supported by background knowledge, the use of the covariate-dependent functions
u(0, X) and δ(X), corresponding to a covariate-dependent u(1, X), should result in more
informative sensitivity analyses. When background knowledge is not that sharp, however,
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the simple approach of examining pairs of
(
u(0), δ
)
over a sufficiently broad range of values,
may be adequate to explore the impact of violations of the transportability condition on
generalizability inferences. Of note, the double robustness property holds regardless of the
dependence of the bias functions on covariates, provided equation (9) is satisfied.
3 Application to the HALT-C trial
3.1 Data and methods
The HALT-C trial and transportability between centers: The HALT-C trial en-
rolled patients with chronic hepatitis C and advanced fibrosis who had not responded to
previous therapy and randomized them to treatment with peginterferon alpha-2a (a = 1)
versus no treatment (a = 0). Patients were enrolled in 10 research centers and followed up
every 3 months after randomization. We used data on the secondary outcome of platelet
count at 9 months of follow-up; we report all outcome measurements as platelets ×103/ml.
To simplify exposition, we only used data from 205 patients (186 with complete data for
our analyses) seen in two different research centers who had complete baseline covariate
and outcome data: the index center, S = 1, contributing 105 patients (94 with complete
data); and the target center, S = 0, contributing 100 patients (92 with complete data). For
purposes of illustration, we treated the target center data as a sample from a population
of (trial-eligible) non-randomized individuals. Our goal was to transport causal inferences
from the index center to the population represented by the target center. Because both cen-
ters were actually participating in the same trial, and because treatment and outcome data
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were available from both, we could compare estimates from transportability and sensitivity
analyses against the randomization-based analyses in the target center. We purposely chose
these two centers because they estimated the treatment effect on the platelet count to be
substantially different (see below). In view of how we created the dataset for this illustration,
our analyses should not be clinically interpreted.
Sensitivity analysis methods: We used bias functions that where constant within levels
of the baseline covariates. Specifically, we examined u(0) values of −40, 0, and +40 and
varied δ from −60 to +60, in steps of 20, examining all possible (u(0), δ) pairs. We chose
this range of values because, across all 10 centers participating in the HALT-C trial, the
difference between the largest and smallest post-treatment mean was approximately 40 for
patients assigned to a = 1 and 56 for patients assigned to a = 0. Furthermore, the standard
deviation of the pre-treatment platelet count across all centers participating in the trial was
approximately 66.1.
We used the bias functions with the estimators provided in the previous section to perform
sensitivity analyses. We obtained confidence intervals for the potential outcome mean under
each treatment using the robust (“sandwich”) variance [26], accounting for the estimation
of the parameters of the working models. In Appendix D we describe an additional example
sensitivity analysis using covariate-dependent bias functions. We conducted all sensitivity
analyses using the R [30] package geex [31].
Model specification: The sensitivity analysis methods require the specification of models
for the outcome mean in each treatment group, the probability of trial participation, and
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the probability of treatment among randomized individuals. We specified logistic regression
models for the probability of being in center S = 1 and the probability of being assigned
to peginterferon alpha-2a (a = 1) among randomized individuals in that center. We also
specified two linear regression models (one for each treatment arm) for the mean of the
outcome among randomized individuals. Baseline covariate information is summarized in
Table C.1; all models used the baseline covariates listed in the table as main effects (baseline
platelets, age, sex, treatment history, race/ethnicity, baseline white blood cell count, history
of using needles or recreational drugs, transfusion history, body mass index, creatinine,
and smoking). We built separate outcome models in each treatment group to allow for
heterogeneity of the treatment effect over all baseline covariates included in the models.
3.2 Results
The “base case” analyses under mean transportability (i.e., u(0) = 0 and δ = 0) produced
similar results across different estimators (Table C.2), suggesting that models were approx-
imately correctly specified [32]. The unadjusted randomization-based analyses among pa-
tients with S = 0 produced fairly different results compared to the transportability analyses
(Table C.3). The differences, however, were much smaller after using an augmented inverse
probability weighting regression estimator to analyze the S = 0 data (because of randomiza-
tion among individuals in S = 0, the covariate adjustment is virtually assumption-free [33]).
The large change in estimates after covariate adjustment in the sample from S = 0 is a
reminder that large baseline covariate imbalances can occur in small samples despite ran-
domization.
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Sensitivity analysis results are summarized in Figure 1 and Appendix Figures C.1. Over-
all, the results were only moderately sensitive to violations of the transportability assump-
tion; for example, regardless of the choice of u(0), values of δ smaller than -25 or -30 (de-
pending on the estimator) would be needed for the estimated average treatment effect in
S = 0 to be in opposite direction compared to the base-case analysis (i.e., the black lines in
the graphs cross only for δ values lower than -25 or -30). Sensitivity analysis results were
much more uncertain when using IO weighting compared to the g-formula or augmented IO
weighting estimators.
4 Discussion
We propose sensitivity analysis methods for violations of exchangeability assumptions in
studies extending inferences from a randomized trial to the population of non-randomized
individuals (in the main text) or the overall target population (in Appendix A). The meth-
ods rely on specifying bias functions that directly parameterize violations of the required
exchangeability assumptions. They can be applied to sensitivity analyses for outcome
model-based (g-formula) estimators, probability of trial participation-based estimators (in-
verse probability or odds weighting), or augmented estimators that combine outcome and
probability of participation models. Because of the additive structure of the bias correction,
our methods are best-suited to continuous outcomes with unbounded support; a different
sensitivity analysis method, suitable for non-continuous outcomes or continuous outcomes
with bounded support, will be the subject of future work.
The augmented weighting estimators are appealing for applied work because of their
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increased robustness to model misspecification. Because all methods depend critically on
the specification of bias functions, which will often be highly speculative, some investigators
might consider the double robustness property to be less compelling in the context of sen-
sitivity analyses compared to when mean transportability holds. Even so, the augmented
weighting estimators may be preferred compared to non-augmented weighting estimators
because of improved efficiency; as illustrated in our analyses of data from the HALT-C trial.
Furthermore, sensitivity analyses can be repeated with different bias functions to examine
whether the choice of function leads to different conclusions regarding sensitivity to violations
of the transportability assumption.
An attractive aspect of our methods is that they do not require detailed background
knowledge about unknown or unmeasured variables. Instead, they only require expert judg-
ments about the magnitude of the aggregate bias that these variables could induce. These
judgments can be informed by examining readily available data on the variation of treat-
ment effects among subgroups defined in terms of observed variables in the data at hand
or external sources, including observational studies; the variation of treatment effects across
studies examining similar interventions and outcomes in different populations (e.g., as as-
sessed in meta-analyses); or the variation of the mean outcome under each treatments across
populations and population subgroups. The benefit of our approach becomes clear when
compared against approaches that require the specification of models for the distribution
of unmeasured variables and the associations between unmeasured and measured variables
(e.g., [11, 12]). These alternative approaches have multiple sensitivity parameters and re-
quire detailed background knowledge about sources of effect heterogeneity; such knowledge
is often unavailable because empirical studies typically do not allow the precise assessment
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of effect modification [34,35].
Some readers might find our sensitivity analysis approach unsatisfactory because it does
not provide a single point estimate, and instead produces a range of results and associated
confidence limits under possible violations of the transportability assumption [9]. We believe
that this is a desirable feature of our approach: when the transportability assumption does
not hold, the data do not contain adequate information to identify the causal quantities
of interest, and at best we can hope to examine how our conclusions would be affected by
different violations of our assumptions. In a sense, we view sensitivity analysis as a way
to encourage inferential modesty in analyses extending trial findings to a target population:
sensitivity analysis highlights that the range of results compatible with the data, when con-
sidering violations of assumptions, is much broader than it appears when solely considering
uncertainty due to sampling variability.
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Figure
Figure 1: Sensitivity analysis results for transporting inferences between two research centers
participating in the HALT-C trial.
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AIOW2 = augmented inverse odds weighting estimator with normalized weights; IOW2 =
inverse odds weighting with normalized weights; OM = outcome model-based estimator.
Results are shown as point estimates (black lines) and corresponding 95% confidence in-
tervals (gray lines) for potential outcome means under treatment a = 1 (solid lines) and
a = 0 (dashed lines). Results for IOW1 and AIOW1 were similar to IOW2 and AIOW2,
respectively, and are shown in the Appendix.
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Appendix A Identification, estimation, and sensitivity
analysis for potential outcome means in
the entire target population
We now summarize methods for the identification, estimation, and sensitivity analysis for
the potential outcome means in the entire target population, E[Y a]. These methods apply
to nested trial designs (i.e., when the randomized trial is nested in a cohort sampled from
the target population).
Identifiability conditions
(I) Consistency: If Ai = a, then Yi = Y
a
i . Again, implicit in our notation is the assumption
that the invitation to participate in the trial and trial participation itself do not affect the
outcome except through treatment assignment.
(II) Mean exchangeability in the trial (over A): E[Y a|X,S = 1, A = a] = E[Y a|X,S = 1].
(III) Positivity of treatment assignment: Pr[A = a|X = x, S = 1] > 0 for every a and every
x with positive density among randomized individuals, fX|S(x|S = 1) > 0.
(IV) Mean generalizability (exchangeability over S): E[Y a|X,S = 1] = E[Y a|X].
(V) Positivity of trial participation: Pr[S = 1|X = x] > 0 for every x with positive density
in the population, fX(x) > 0.
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Identification
Under the identifiability conditions listed above, the potential outcome mean among the
target population is identifiable as
E[Y a] = E
[
E[Y |X,S = 1, A = a]] (A.1)
= E
[
SI(A = a)Y
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
, (A.2)
where the second equality only requires the positivity conditions [6].
Estimation
Potential outcome means: The identification results above suggest several ways for es-
timating the potential outcome mean in the target population. In this section, we use the
same notation as in the main text, except that we use the tilde symbol to denote estimators.
Additional information about the behavior of estimators when the mean transportability
assumption holds are available in [5].
g-formula estimator: We can use the sample analog estimator based on (A.1),
µ˜OR(a) =
1
n
n∑
i=1
ĝa(Xi). (A.3)
Inverse probability (IP) weighting: We can use an estimator based on (A.2)
µ˜IPW1(a) =
1
n
n∑
i=1
w˜a(Xi, Si, Ai)Yi, (A.4)
with
w˜a(Xi, Si, Ai) =
SiI(Ai = a)
p̂(Xi)êa(Xi)
.
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We can normalize the weights to sum to 1,
µ˜IPW2(a) =
{
n∑
i=1
w˜a(Xi, Si, Ai)
}−1 n∑
i=1
w˜a(Xi, Si, Ai)Yi. (A.5)
Augmented IP weighting: To improve the efficiency of the IP weighting estimator and allow
for robustness to misspecification of the outcome mean or probability of trial participation
models, we can use an augmented (doubly robust) IP weighting estimator [5],
µ˜AIPW1(a) =
1
n
n∑
i=1
{
w˜a(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+ ĝa(Xi)
}
, (A.6)
Again, it is often better to normalize the weights to sum to 1,
µ˜AIPW2(a) =
{
n∑
i=1
w˜a(Xi, Si, Ai)
}−1 n∑
i=1
w˜a(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+
1
n
n∑
i=1
ĝa(Xi). (A.7)
Treatment effects: We can use the above potential outcome mean estimators, to estimate
the average treatment effect in the target population, E[Y 1 − Y 0], by differencing.
Inference
As usual, confidence intervals for the estimated potential outcome means and mean differ-
ences can be obtained by the usual “sandwich” approach [26] or by bootstrap methods [27].
Sensitivity analysis
As in the main text, we parameterize violations of the transportability assumption using the
bias functions [9, 28,29]
u(a,X) = E[Y a|X,S = 1]− E[Y a|X,S = 0].
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The parameterization allows us to re-express the conditional potential outcome mean
under treatment a,
E[Y a|X] = E[Y a|X,S = 1] Pr[S = 1|X] + E[Y a|X,S = 0] Pr[S = 0|X]
= E[Y |X,S = 1, A = a] Pr[S = 1|X]
+
{
E[Y |X,S = 1, A = a]− u(a,X)}Pr[S = 0|X]
= E[Y |X,S = 1, A = a]− u(a,X) Pr[S = 0|X],
where the first equality follows from the law of total expectation; the second from consistency
and mean exchangeability in the trial together with the definition of u(a,X); and the third
from the fact that S is binary.
Taking expectations over the distribution of X in the target population,
E[Y a] = E
[
E[Y |X,S = 1, A = a]− u(a,X) Pr[S = 0|X]]
= E
[
E[Y |X,S = 1, A = a]]− E[u(a,X) Pr[S = 0|X]]
= E
[
E[Y |X,S = 1, A = a]]− E[(1− S)u(a,X)],
(A.8)
where the last equality follows from the law of total expectation.
Sensitivity analysis estimators: The result in (A.8) suggests simple approaches for sen-
sitivity analysis using the potential outcome mean estimators in the previous section.
g-formula estimator: We can incorporate the bias correction function directly,
µ˜bc
OR
(a) =
1
n
n∑
i=1
{
ĝa(Xi)− (1− Si)u(a,Xi)
}
. (A.9)
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IP weighting: Similarly, we can modify the IP weighting estimators as
µ˜bc
IPW1
(a) =
1
n
n∑
i=1
{
w˜a(Xi, Si, Ai)Yi − (1− Si)u(a,Xi)
}
, (A.10)
or, normalizing the weights to sum to 1,
µ˜bc
IPW2
(a) =
{
n∑
i=1
w˜a(Xi, Si, Ai)
}−1 n∑
i=1
w˜a(Xi, Si, Ai)Yi − 1
n
n∑
i=1
(1− Si)u(a,Xi). (A.11)
In the next section of this Appendix, we show how the bias correction for the IP weighting
estimators can be easily implemented using standard regression software, by simply re-coding
the outcome values to directly incorporate the bias correction function u(a,X).
Augmented IP weighting: We can incorporate the bias correction functions in the augmented
IP weighting estimators,
µ˜bc
AIPW1
(a) =
1
n
n∑
i=1
{
w˜a(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+ ĝa(Xi)− (1− Si)u(a,Xi)
}
, (A.12)
or, normalizing the weights to sum to 1,
µ˜bc
AIPW2
(a) =
{
n∑
i=1
w˜a(Xi, Si, Ai)
}−1 n∑
i=1
w˜a(Xi, Si, Ai)
{
Yi − ĝa(Xi)
}
+
1
n
n∑
i=1
{
ĝa(Xi)− (1− Si)u(a,Xi)
}
.
(A.13)
These augmented IP weighting estimators retain the double robustness property of their
non-bias corrected counterparts, in the sense that, when the bias correction function is cor-
rectly specified, they produce valid results when either the model of the outcome mean among
randomized individuals or for the probability of trial participation is correctly specified.
Sensitivity analysis for treatment effects: As when the transportability assumption
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holds, sensitivity analysis for treatment effects can be obtained by differencing the appropri-
ate bias-corrected estimators.
Inference for sensitivity analysis
The general theory for sensitivity analysis for semi-parametric models in [9] shows that
confidence intervals for the estimated bias-corrected potential outcome means and mean
differences can also be obtained by “sandwich” or bootstrap [27] methods, while accounting
for the uncertainty in estimating the parameters of the model for the probability of trial
participation.
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Appendix B Sensitivity analysis with bias-corrected
outcomes
We now demonstrate the connection between our approach for sensitivity analysis and the
method of using “bias corrected outcomes” in marginal structural models [28,29].
Sensitivity analysis with bias-corrected outcomes for E[Y a|S = 0]: Define the bias
corrected outcomes
Y ∗i = Yi − u(Ai, Xi)
and assume that bias functions u(a,X) have been properly chosen, so that, for every a,
u(a,X) = E[Y a|X,S = 1]− E[Y a|X,S = 0].
The estimator
µ̂bc obs
IOW
(a) =
{
n∑
i=1
ŵa(Xi, Si, Ai)
}−1 n∑
i=1
ŵa(Xi, Si, Ai)Y
∗
i ,
with
ŵa(Xi, Si, Ai) = SiI(Ai = a)
1− p̂(Xi)
p̂(Xi)êa(Xi)
,
converges in probability to the same limit as the estimators in (13) and (14). The bias-
corrected outcome estimator above can be obtained by running a weighted least squares
regression of Y ∗ on A with weights ŵa(Xi, Si, Ai).
Sensitivity analysis with bias-corrected outcomes for E[Y a]: For each trial partici-
pant, define the bias-corrected outcome
Y˜ ∗i = Yi − u(Ai, Xi)
{
1− p̂(Xi)
}
.
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The estimator
µ̂bc obs
IPW
(a) =
{
n∑
i=1
w˜a(Xi, Si, Ai)
}−1 n∑
i=1
w˜a(Xi, Si, Ai)Y˜
∗
i ,
with
w˜a(Xi, Si, Ai) =
SiI(Ai = a)
p̂(Xi)êa(Xi)
,
converges in probability to the same limit as estimators (A.10) and (A.11). The bias-
corrected outcome estimator above can be obtained by running a weighted least squares
regression of Y˜ ∗ on A with weights w˜a(Xi, Si, Ai).
Inference for sensitivity analysis using bias corrected outcomes: Inference for the
potential outcome means and treatment effects when using bias-corrected observations is
best obtained using bootstrap methods [28].
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Appendix C Additional HALT-C results
In this Appendix we report additional results from the re-analysis of data from the HALT-C
trial.
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Table C.2: “Base case” transportability analyses using center S = 0 as the “target center”
and assuming conditional mean transportability holds (u(0) = 0 and δ = 0); 95% confidence
intervals are given in parentheses.
Estimator a = 1 a = 0 Mean difference
OM 126.81 (111.03, 142.59) 178.38 (161.49, 195.27) -51.57 (-70.49, -32.65)
IOW1 122.60 (99.33, 145.87) 175.66 (120.76, 230.56) -53.06 (-116.47, 10.35)
IOW2 118.26 (98.91, 137.61) 182.87 (147.63, 218.11) -64.61 (-100.55, -28.67)
AIOW1 127.55 (112.13, 142.97) 177.27 (161.87, 192.67) -49.72 (-67.44, -32.00)
AIOW2 127.53 (112.11, 142.95) 177.23 (161.87, 192.59) -49.70 (-67.37, -32.03)
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Table C.3: Crude and adjusted analyses in each research center contributing data to the
transportability analyses; 95% confidence intervals are given in parentheses.
Center Estimate a = 1 a = 0 Mean difference
S = 1
Crude 130.87 (110.6, 151.13) 155.77 (135.93, 175.61) -24.9 (-53.26, 3.46)
Adjusted 130.47 (112.25, 148.69) 166.86 (150.2, 183.52) -36.39 (-55.64, -17.14)
S = 0
Crude 119.87 (97.54, 142.2) 204.8 (182.48, 227.13) -84.93 (-116.51, -53.36)
Adjusted 128.37 (115.62, 141.12) 190.47 (168.07, 212.87) -62.1 (-85.19, -39.01)
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Figure C.1: Sensitivity analysis using the inverse odds of participation estimator with non-
normalized weights (IOW1) and the augmented inverse odds of participation estimator with
non-normalized weights (AIOW1).
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Appendix D Sensitivity analysis with covariate-dependent
bias functions
To illustrate the application of the sensitivity analysis methods when the bias functions
depend on covariates, we considered a sensitivity analysis where the bias functions depended
on sex (coded as male vs. female). Without loss of generality, let the first element of X, X1,
be a random variable that takes the value 1 for male and 0 for female individuals. We set
up the bias function for a = 0 as
u(0, X) ≡ I(X1 = 1)× u(0) + 0.8× I(X1 = 0)× u(0),
such that the magnitude of assumption violations is smaller by 20% among female individuals
versus male individuals. Similarly, we set the difference of the bias functions to
δ(X) ≡ I(X1 = 1)× δ + 0.8× I(X1 = 0)× δ.
Figure D.1 presents sensitivity analysis results using the bias functions described above.
Comparing the results plotted in Figure D.1 against those in Figure 1, we see that sensitivity
is slightly reduced. The reason is that violations of transportability assumption in Figure
D.1 are assumed to be the same among male but smaller (by 20%) among female individuals,
compared to the corresponding values used for Figure 1.
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Figure D.1: Sensitivity analysis results for transporting inferences between two research
centers participating in the HALT-C trial using bias functions that depend on baseline
covariates.
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = -40
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 0
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 40OM     
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = -40
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 0
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 40IOW2  
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = -40
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 0
0
100
200
300
Ê[
Ya
|S
 =
 0
]
-40 -20 0 20 40
δ
u(0) = 40AIOW2
AIOW2 = augmented inverse odds weighting estimator with normalized weights; IOW2 =
inverse odds weighting with normalized weights; OM = outcome model-based estimator.
Results are shown as point estimates (black lines) and corresponding 95% confidence in-
tervals (gray lines) for potential outcome means under treatment a = 1 (solid lines) and
a = 0 (dashed lines). Results for IOW1 and AIOW1 were similar to IOW2 and AIOW2,
respectively, and are not shown here.
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